IL-29 Inhibitors
Chemical Class Description: The class of IL-29 inhibitors includes a range of compounds that indirectly modulate the activity of IL-29 by targeting various signaling pathways and cellular processes. These compounds do not interact directly with IL-29 but influence the cellular environment and mechanisms in which IL-29 operates. JAK inhibitors like JAK Inhibitor I, Ruxolitinib, and Tofacitinib target the JAK-STAT pathway, which is crucial for the signal transduction of IL-29. STAT inhibitors such as Stattic, WP1066, and S3I-201 disrupt STAT3 phosphorylation and activity, key components of IL-29 signaling.
AG490, as a tyrosine kinase inhibitor, and Sorafenib, as a broad kinase inhibitor, might impact signaling pathways related to IL-29's immune-modulating functions. Curcumin, with its wide-ranging effects on cellular signaling, and BAY 11-7082, an NF-κB inhibitor, represent different mechanisms of potentially modulating IL-29's activities. LY294002, a PI3K inhibitor, and SB203580, a p38 MAPK inhibitor, further illustrate diverse approaches to influencing signaling pathways associated with IL-29.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Inhibits STAT3, a key component in the JAK-STAT signaling pathway influenced by IL-29. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor, might modulate the JAK-STAT pathway involved in IL-29 signaling. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
Inhibits STAT3 phosphorylation, potentially affecting STAT3-mediated signaling by IL-29. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrosine kinase inhibitor, might impact JAK-STAT signaling in IL-29 pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor, could influence downstream effects of IL-29 signaling. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
STAT3 inhibitor, potentially disrupting STAT3-dependent signaling in IL-29 pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Kinase inhibitor, might modulate pathways involved in IL-29 signaling. | ||||||